Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation
Junzhi Liu, Xiaoyu Zuo, Xue Yang, Xinyue Wang, Lu Gan, Jianxin Xue · 2026
Read Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation by Junzhi Liu, Xiaoyu Zuo, Xue Yang, Xinyue Wang, Lu Gan, Jianxin Xue (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471678.txt.
Description
Junzhi Liu and five colleagues published a 2026 review of a new lung cancer treatment that pairs a radioactive particle with a drug aimed at tumour cells. These paired agents, called radionuclide-drug conjugates, deliver radiation precisely to tumours while also allowing imaging. Lung cancer remains the leading cause of cancer death worldwide, and current drugs often fail as tumours resist treatment or vary from cell to cell.
The review searched published work and trial records up to January 2026, finding 66 such agents screened and 30 already in early human trials. Most work centres on a target called SSTR, with newer interest in FAP, EGFR, and PD-L1, and with lutetium-177 still the main radioactive ingredient. Toxicity away from tumours, radiation resistance, and supply of radioactive material remain the main barriers to wider use.
Catalog record
| CREATOR | Junzhi Liu, Xiaoyu Zuo, Xue Yang, Xinyue Wang, Lu Gan, Jianxin Xue |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 106 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |